



NOVEMBER 12-15, 2024 LONDON, UK

Conference Daily Program – Draft

Tuesday 12th November

- 12:00pm** **Conference Check-In & Registration Opens**
- 1:15pm** **Welcome to ICAR 2024**
Welcome from Ataxia UK and the Ataxia Global Initiative
Venue: *Trinity & Goodmans Suite*
- 1:30pm** **Keynote Speaker: The NINDS Research Investment in Ataxia**
Dr Walter Koroshetz, (National Institute of Neurological Disorders and Stroke)
Venue: *Trinity & Goodmans Suite*
- 2:10pm** **Patient Panel: Living with Ataxia**
Venue: *Trinity & Goodmans Suite*
- Chaired by: Sue Millman (Ataxia UK)
- 3:00pm** **Refreshments Break**
- | | | |
|--|--|--|
| <p>3:30pm Parallel sessions
 Venue: <i>Trinity & Goodmans Suite</i></p> | <p>Workshops
 <i>Minories Suite</i></p> | |
| <p>Parallel session: Disease mechanisms I</p> | <p>Workshop: A diagnostic approach to the ataxias</p> | |

Chaired by:	Dr. Marek Napierala (University of Texas Southwestern Medical Center), Prof. Nicole Deglon (Lausanne University Hospital)	Prof. Marios Hadjivassiliou (Sheffield Ataxia Centre) Martin Paucar MD, PhD (Karolinska University Hospital)
3:30	AAGGG/CCCTT repeat expansions trigger RFC1-independent synaptic dysregulation in human CANVAS Neurons <u>Dr. Connor Maltby</u> (University of Michigan)	The workshop will focus on the diagnostic approach to ataxia, highlighting clues (pattern recognition) that may enable the clinician to reach a diagnosis.
3:45	Action potential propagation failures in Purkinje cell axons in a mouse model of ARSACS <u>Dr. Amy Smith-Dijak</u> (McGill University)	
4:00	Neuroinflammatory responses in Gluten ataxia <u>Dr. Mara-Luciana Floare</u> (University of Sheffield)	
4:15	Early molecular and electrophysiological alterations of the calcium channel Cav2.1 precede Purkinje cells degeneration in the ARSACS mouse model <u>Dr. Erica Spirito</u> (IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University)	
4:30	Deciphering the Molecular Mechanisms: Investigating Dysregulated Pathways in Frataxin-Deficient Proprioceptive Neurons <u>Ms. Deepika Mokkachamy Chellapandi</u> (Institut NeuroMyoGène, INSERM, Université Claude Bernard Lyon I)	
4:37	The Role of Astrocytes in Sca1 pathogenesis	

	<u>Dr. Caleb Smith</u> (Northwestern University)
4:44	From Molecular Mechanisms to Clinical Correlations: Advancing SCA48 Therapeutics <u>Dr. Jonathan Schisler</u> (University of North Carolina at Chapel Hill)
4:51	CACNA1A haploinsufficiency leads to reduced synaptic function and increased intrinsic excitability <u>Mrs. Marina Hommersom</u> (Radboud University Medical Center)

5:00pm **Plenary – Debate on controversial ataxia research topics**
Venue: *Trinity & Goodmans Suite*

1. Can cellular models replace animal models?
Debaters: Prof. Esther Becker (University of Oxford) and Dr H el ene Puccio (Institut NeuroMyoG ene, INSERM, Universit e Claude Bernard Lyon I)
2. Should we stop focusing on ASOs in dominant ataxias?
Debaters: Dr Nicole Datson (VICO Therapeutics BV) and Dr Vikram Shakkottai (University of Texas Southwestern Medical Center)

Chaired by: Prof. Alexandra Durr (Sorbonne University, Paris Brain Institute, Piti -Salp tri re Hospital), Dr. Anoopum Gupta (Massachusetts General Hospital and Harvard Medical School)

6:00pm **Funding opportunities from CDMRP - Brigid Brennan (FARA)**
Venue: *Trinity & Goodmans Suite*

6:10-7:30pm **Welcome Reception & Poster Session I**
Venue: *Minorities Suite*

Biomarkers and clinical outcomes, Emerging and existing therapeutics - clinical research, Cell and animal models

Wednesday 13th November

7.45-8.45am **Presenting Sponsor Breakfast Symposium**
Venue: *Trinity & Goodmans Suite*

Translating research to practice: Omaveloxolone as a novel treatment for Friedreich ataxia

8:55am **Welcome from the National Ataxia Foundation**

9:00am **Plenary session: Advances in genetics and diagnostics**

Venue: *Trinity & Goodmans Suite*

Chaired by: Prof. Bart van de Warrenburg (Radboud University Medical Center), Dr. Penina Ponger (Tel Aviv Sourasky Medical Center)

9:00am **Invited speaker:** How to solve the unsolved: Repeat expansions in ataxia, genetics, tools and new sequencing methods
Prof Christel Depienne (University of Duisburg-Essen)

9:30 A common flanking variant is associated with enhanced stability of the FGF14-SCA27B repeat locus

Dr. David Pellerin (University of Miami Miller School of Medicine)

9:45 Long-read genomic sequencing reveals expanded GAA-GGA chimeric alleles in Friedreich ataxia

Prof. Sanjay Bidichandani (University of Oklahoma Health Sciences Center)

10:00 Spinocerebellar ataxia type 4: a novel polyglycine disorder caused by GGC repeat expansion in ZFH3.

Prof. Stefan Pulst (University of Utah)

10:15 Population analysis of repeat expansions indicates increased frequency of pathogenic alleles disease across different populations

Dr. Arianna Tucci (Queen Mary University of London)

10:30am **Refreshments Break**

11:00am **Parallel sessions**

Venue: *Trinity & Goodmans Suite*

Workshops

Minories Suite

Chaired by:

Parallel session: Cellular and Animal Models

Prof. Luís Pereira de Almeida (Center for Neuroscience and Cell Biology, University of Coimbra), Ms. Alexa Putka (University of Michigan)

Workshop: Imaging

Dr. Jennifer Faber (German Center for Neurodegenerative Diseases)
Dr. Gulin Oz (University of Minnesota)

11:00	<p>A missense mutation in the CCDC88C gene induces cerebellar neurodegeneration and activation of mixed lineage kinase in a knock-in mouse model of SCA40 <u>Edwin Chan</u> (The Chinese University of Hong Kong)</p>	<p>This workshop will provide an introductory overview of common human MRI acquisition approaches, analysis tools, and outcome measures that are used in ataxia research and clinical trial contexts.</p>
11:15	<p>Phosphodiesterase inhibitors improve Friedreich's Ataxia conditions by correcting cofilin pathway and mitochondrial distribution in Drosophila models <u>Mr. Alexandre Llorens Trujillo</u> (INCLIVA, Biomedical Research Institute, University of Valencia)</p>	
11:30	<p>Unraveling the cause of phenotypic heterogeneity in spinocerebellar ataxia-type 47 (SCA47): distinct mutations, distinct mechanisms <u>Mr. Maximilian Cabaj</u> (Columbia University Irving Medical Center)</p>	
11:45	<p>Time-specific inactivation of FXN gene reveals its essential early post-development role: insights from a new mouse model and human DRG organoids. <u>Dr. Agostina Di Pizio</u> (IRCCS San Raffaele Hospital)</p>	
12:00	<p>Modelling Spinocerebellar Ataxia Type 29 (SCA29) in Cerebellar Organoids with Loss-of-Function and Gain-of-Function Variants in the ITPR1 gene <u>Dr. Jussi-Pekka Tolonen</u> (University of Oulu)</p>	
12:07	<p>A novel transgenic mouse model of spinocerebellar ataxia type 2 bearing 129 CAG repeats: neuropathologic and phenotypic characterization <u>Prof. Carlos Matos</u> (University of Algarve)</p>	

12:14	<p>Comprehensive Analysis of the CACNA1A SCA6 protein, a1ACT: Insights from Transgenic Mouse Models and Multi-Omics Approaches for SCA6 Pathogenesis</p> <p><u>Dr. Xiaofei Du</u> (The University of Chicago)</p>
12:21	<p>Unraveling Peripheral Neuropathy in Spinocerebellar Ataxia Type 3: Insights from a Mouse Models</p> <p><u>Dr. Hayley McLoughlin</u> (University of Michigan)</p>

12:30-2pm Lunch

1:00pm Mentoring sessions: Science in Academia and Clinical Research
Venue: *Minories Suite*

2:00pm Parallel sessions
Venue: *Trinity & Goodmans Suite*

Workshops
Minories Suite

	Parallel session: Biomarkers and clinical outcome measures I	Workshop: Disease models of cerebellar ataxia – what are they useful for?
Chaired by:	Prof. Matthis Synofzik (University of Tübingen), Dr. Sheng-Han Kuo (Columbia University Medical Center)	Prof. Esther Becker (University of Oxford) Magda Matos Santana (University of Coimbra) Dr. Ronald Buijsen (Leiden University)
2:00	Predictive models for ataxia progression and conversion in SCA1 and SCA3 <u>Mr. Emilien Petit</u> (Sorbonne University, INRIA, CNRS, APHP)	This workshop will explore some of the challenges associated with choosing a model system. What makes a good model? What have we learned from using model systems? What questions can be addressed using different model systems? What are the limitations of different models?
2:15	Genotype-specific Spinal Cord Damage in Spinocerebellar Ataxias: an ENIGMA-Ataxia Study	Moderators:

Dr. Thiago Rezende (State University of Campinas)

Prof Patrícia Maciel (University of Minho School of Medicine), Dr Laura Ranum (University of Florida), Dr Walfred Tang (Insmed)

2:30

Delineating the phenotypic spectrum and FGF14 GAA repeat size pathogenic threshold in a large French-Canadian SCA27B cohort

Dr. Felipe Villa (McGill University)

2:45

Preliminary natural history data in Spinocerebellar Ataxia type 44 (SCA44) reveals marked speech impairment compared to other metrics

Prof. Andrea Nemeth (University of Oxford)

3:00

Longitudinal analysis of clinical outcomes and plasma NfL, total tau, GFAP and UCHL1 in spinocerebellar ataxia type 3/Machado-Joseph disease.

Dr. Hector Garcia-Moreno (University College London)

3:07

Comparison of Two Matching Methods to Assess Effectiveness of Trotiluzole versus Untreated Natural History Cohort in Spinocerebellar Ataxia

Dr. Michele Potashman (Biohaven Pharmaceuticals, Inc.)

3:14

Measuring Friedreich Ataxia in children – exploring how typically developing children perform on clinical rating scales.

Dr. Louise A Corben (Murdoch Children's Research Institute, University of Melbourne, Monash University)

3:21 In-clinic Eye Tracking during Passage Reading Supports Precise Assessment of Oculomotor Signs of Ataxia
Dr. Brandon Oubre (Massachusetts General Hospital and Harvard Medical School)

3:30pm Refreshments Break

4:00pm Parallel Sessions
Venue: *Trinity & Goodmans Suite*

Workshops
Minories Suite

Parallel session: Imaging
Chaired by: Dr. Gulin Oz (University of Minnesota), Dr. Thiago Rezende (University of Campinas)

4:00 Neuroimaging biomarkers of hypoplasia and disease progression in Friedreich Ataxia: preliminary 12-month longitudinal results from TRACK-FA
Prof. Pierre-Gilles Henry (University of Minnesota)

4:15 Longitudinal evaluation brain structural changes in RFC1-related disorder
Dr. Camila Lobo (State University of Campinas)

4:30 Dorsal root ganglia and spinal cord imaging in genetic and acquired sensory neuropathies
Mrs. Rafaella Tacla (State University of Campinas)

Workshop: Gene Therapy at the Crossroads - Triumphs, Challenges, and Future Directions
Prof. Luís Pereira de Almeida (University of Coimbra)
Prof. Nicole Deglon (Lausanne University Hospital)

This workshop will explore the current state of gene therapy, highlighting both its successes and ongoing challenges. By examining the field's historical context and recent breakthroughs, we aim to foster discussions on overcoming remaining obstacles and realizing the full potential of gene therapy in addressing unmet medical needs.

Speakers
Prof Luís Pereira de Almeida (University of Coimbra)
Prof Nicole Déglon (Lausanne University Hospital)

4:45 | Reduced Mitochondrial Complex 1 density in the brain and heart of Friedreich's ataxia patients revealed using [18F]BCPP-EF PET imaging
| Prof. Richard Festenstein (Imperial College London) |

5:00pm **Grand Rounds**
Venue: *Trinity & Goodmans Suite*

Chaired by:

Prof. Massimo Pandolfo (McGill University), Prof. Alexandra Durr (Sorbonne University)

Presenters:

Prof. Sanjay Bidichandani (University of Oklahoma Health Sciences Center) and Prof. David Lynch (Children's Hospital of Philadelphia)
Dr Claire Ewencyk (Sorbonne Université, Paris Brain Institute, Inserm, CNRS)
Prof. Massimo Pandolfo (McGill University)
Prof. Marios Hadjivassiliou (Sheffield Ataxia Centre)

6:00-7:30pm **Drink Reception & Poster Session II**
Venue: *Minories Suite*

Advances in genetics and diagnostics, Cerebellar neurodevelopment and cognitive disorders, Cerebellar circuits and function, Disease mechanisms, Imaging, Emerging and existing therapeutics – preclinical research

Thursday 14th November

8:55am **Welcome from the Friedreich's Ataxia Research Alliance**

9:00am **Plenary session: Cerebellar Neurodevelopment and Cognitive Disorders**
Venue: *Trinity & Goodmans Suite*

Chaired by: Dr. Giulia Coarelli (Sorbonne University, Paris Brain Institute, Pitié-Salpêtrière Hospital), Dr. Jussi-Pekka Tolonen (University of Oulu)

9:00am **Invited speaker:** Human cerebellar development: from cells to disease
Dr. Kimberly Aldinger (Seattle Children's Research Institute)

- 9:30 Cognitive impairment in SCA3: a multi-center cohort study with demographic and biomarker correlates
Dr. Roderick Maas (Radboud University Medical Center)
- 9:45 Cognitive performance and its correlates in spinocerebellar ataxia types 1, 2, 3, and 6
Dr. Louisa P. Selvadurai (Monash University)
- 10:00 Cerebellar contribution to cognitive deficits and prefrontal cortex dysfunction in SCA1
Dr. Marija Cvetanovic (University of Minnesota)
- 10:15 Cognition in spinocerebellar degenerations measured by CCAS scale
Dr. Giulia Coarelli (Sorbonne University, Paris Brain Institute, Pitié-Salpêtrière Hospital)

10:30am Refreshments Break

11:00am Parallel sessions
Venue: *Trinity & Goodmans Suite*

Workshops
Minories Suite

<p>Chaired by:</p>	<p>Parallel session: Disease Mechanism II</p> <p>Martin Paucar MD, PhD (Karolinska University Hospital), Dr. Magda Santana (University of Coimbra)</p>	<p>Workshop: Current and future digital and fluid biomarkers for ataxia trials</p> <p>Dr. Anoopum Gupta (Massachusetts General Hospital and Harvard Medical School) Dr. Giulia Coarelli (Sorbonne University)</p>
<p>11:00</p>	<p>A PRKN missense polymorphism modifies the age at onset in Spinocerebellar Ataxia Type 3 (SCA3) and impacts protein-protein interaction as well as mitophagy</p> <p><u>Dr. Thorsten Schmidt</u> (Eberhard Karls University)</p>	<p>The goal of this workshop is to become familiar with a few of the most promising fluid and digital biomarkers for use in ataxia clinical trials to help determine efficacy and target engagement. How were these biomarkers discovered, why are they exciting, and what are their limitations? What does the next generation of biomarkers look like and how will we get there?</p>

11:15	<p>Purkinje-Enriched snRNA-seq in SCA7 Cerebellum Reveals Zebrin-II Stripe Loss as a Shared Feature of Polyglutamine Ataxias</p> <p><u>Prof. Albert La Spada</u> (University of California Irvine)</p>	<p>Speakers: Digital biomarkers of gait <u>Dr. Vrutang Shah</u> (Clario) Blood and CSF biomarkers <u>Dr. Paola Giunti</u> (University College London)</p>
11:30	<p>Repeat associated non-AUG translation as a common mechanism for the polyGln ataxias</p> <p><u>Dr. Monica Banez Coronel</u> (University of Florida)</p>	<p>Digital biomarkers of speech <u>Dr. Adam Vogel</u> (University of Melbourne) Digital oculomotor biomarkers <u>David Szmulewicz</u> (University of Melbourne)</p>
11:45	<p>Identification of genetic modifiers of somatic GAA repeat instability in Friedreich's ataxia by in vivo CRISPR-Cas9 genome editing</p> <p><u>Mr. Maheswaran Kesavan</u> (Massachusetts General Hospital)</p>	
12:00	<p>Development of a cellular ataxin-3 protein-protein interaction assay for high-throughput screening of PPI modifiers</p> <p><u>Ms. Ana Rita Fernandes</u> (University of Minho)</p>	
12:07	<p>Dysregulated Lipid Profiles in Cerebellar Tissues of SCA3 Mice and Human Patients</p> <p><u>Ms. Alexa Putka</u> (University of Michigan)</p>	
12:14	<p>What is required for GAA repeat expansion at the endogenous Friedreich's ataxia locus?</p> <p><u>Dr. Marek Napierala</u> (University of Texas Southwestern Medical Center)</p>	
12:21	<p>Nano narratives: unraveling spinocerebellar ataxia type 2 pathogenesis through exosomes</p> <p><u>Mr. Rafael Costa</u> (University of Algarve)</p>	

12:30-2pm Lunch

1:00pm **Mentoring sessions: Science in Industry and Careers in Government and Nonprofits**

Venue: *Minories Suite*

2:00pm **Parallel sessions**
Venue: *Trinity & Goodmans Suite*

Workshops
Minories Suite

	Parallel session: Emerging and Existing Therapeutics - Pre-Clinical Research	Workshop: Towards Preventive Clinical Trials in ataxias
Chaired by:	Dr. Marek Napierala (University of Texas Southwestern Medical Center), Ms. Laurie Kerkhof (Leiden University Medical Center)	Prof. Bart van de Warrenburg (Radboud university medical center) Dr. Susan Perlman (University of California, Los Angeles)
2:00	CRISPR-Cas9-mediated ATXN3 gene inactivation as a potential therapeutic approach for Machado-Joseph disease <u>Dr. Sara Lopes</u> (University of Coimbra)	We need to address specific challenges to be prepared for the exciting scenario of preventive trials in SCAs. In this workshop, we want to discuss some of these challenges, and aim to jointly generate a set of research priorities and next steps.
2:15	Base editing of pathogenic GAA repeats reduces somatic repeat expansions in Friedreich's ataxia <u>Dr. Zaneta Matuszek</u> (Broad Institute and Harvard University)	Speakers <u>Dr. Jennifer Faber</u> (German Center for Neurodegenerative Diseases - DZNE) Measuring the pre-ataxia stage in SCAs - current status and common pitfalls
2:30	Allele-specific silencing of mutant ataxin-3 via single administration of AAV9 vectors mitigates neuropathology and motor deficits in Spinocerebellar Ataxia Type 3 <u>Ms. Ana Carolina Silva</u> (University of Coimbra)	<u>Prof. Sarah Tabrizi</u> (University College London) Working towards prevention trials in Huntington's disease <u>Shana de Figueiredo Scholtz</u> (patient representative, Ataxia UK) The patient perspective on preventive trials in ataxia
2:45	Effects of the novel therapeutic SBT-589 across models of Friedreich's ataxia <u>Dr. Laura Kropp</u> (Stealth BioTherapeutics)	

- 3:00 Pharmacological potentiation of mitochondria-mediated integrated stress response is beneficial for Spastic Ataxia type 5 preclinical models
Dr. Francesca Maltecca (IRCCS Ospedale San Raffaele)
- 3:07 Screening approach for the discovery of molecules replacing Frataxin in Fe-S cluster biosynthesis for the treatment of Friedreich's ataxia
Dr. Benoit D'Autreaux (CNRS, CEA, Université Paris-Saclay)
- 3:14 CAG repeat-selective compounds reduce abundance of expanded CAG RNAs in patient cell and murine models of SCAs
Dr. Hannah Shorrock (University of Albany)
- 3:21 NMDAR-TRPM4 coupling drives neurotoxicity and disease progression in models of spinocerebellar ataxias
Mr. David Brito (Algarve Biomedical Center – Research Institute)

3:30pm Refreshments Break

4:00pm Parallel Sessions
Venue: *Trinity & Goodmans Suite*

Workshops
Minorities Suite

Chaired by:

Parallel session: Emerging and Existing Therapeutics - Clinical Research

Prof. Marios Hadjivassiliou (Sheffield Ataxia Centre), Dr. Thomas Klockgether (German Center for Neurodegenerative Diseases - DZNE)

Workshop: AI Tools for Research

Dr. Jennifer Faber (German Center for Neurodegenerative Diseases), Dr. Thiago Rezende (State University of Campinas)

4:00	<p>Longitudinal progression, SARA metrics, and a sustained modifying effect of 4-aminopyridine treatment in SCA27B: a multicenter study in 219 patients</p> <p><u>Dr. Andreas Träschütz</u> (University of Tübingen)</p>	<p>Within this workshop we are going to have a general introduction to AI and common terms used within the field of AI methodologies, such as Machine Learning, Neural Networks, Dice score and ground truth annotations. In addition, we will highlight three different applications of AI methods:</p>
4:15	<p>Home- and Clinic-Based Rehabilitation Programs for People Living with ARSACS</p> <p><u>Prof. Elise Duchesne</u> (University of Laval)</p>	<p>(1) the search for disease-causing genes, (2) automated segmentations and lesion detections of MR images and (3) digital gait assessments and feature identification using explainable AI.</p>
4:30	<p>Home Balance Verse Aerobic Training: A Randomized Controlled Trial</p> <p><u>Dr. Scott Barbuto</u> (Columbia University Medical Center)</p>	
4:45	<p>Safety and Efficacy of Vatiquinone Treatment in Friedreich Ataxia Patients from MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial</p> <p><u>Prof. David Lynch</u> (Children's Hospital of Philadelphia)</p>	
5:00	<p>A clinical update from a first-in-human, phase 1/2a trial of the CAG repeat-targeting ASO VO659 in patients with Spinocerebellar ataxia types 1 and 3 and Huntington's disease</p> <p><u>Dr. Scott Schobel</u> (VICO Therapeutics BV)</p>	
5:15	<p>Post hoc subgroup analysis: age of Friedreich ataxia onset in MOXIe trial of omeveloxolone</p> <p><u>Prof. David Lynch</u> (Children's Hospital of Philadelphia)</p>	

5:22 | Effect of nomlabofusp administration on tissue frataxin levels, plasma lipid profiles, and gene expression in patients with Friedreich's ataxia
Dr. Russell Clayton (Larimar Therapeutics, Inc.)

6:00pm **Leave hotel for off-site dinner**

6:30pm **Dinner on Thames River Boat**
This is an optional off-site networking dinner, where a light meal will be provided. This event is not paid for by any industry sponsors. Places were allocated on a first-come first-served basis and the event is now fully booked.

Friday 15th November

9:00am **Plenary session: Emerging and Existing Therapeutics**
Venue: *Trinity & Goodmans Suite*

9:00am **Invited speaker:** Molecular and synaptic adaptations promote resilience in posterior SCA6 cerebellum, Dr. Alanna Watt (McGill University)

Chaired by: Dr. Susan Perlman (University of California at Los Angeles), Dr. Helene Puccio (Institut Neuromyogène, Inserm U1315, CNRS-Université Claude Bernard Lyon 1)

9:30 Atrophin-1 Antisense Oligonucleotides Provide Robust Protection from Pathology in a Novel Humanized DRPLA Model
Dr. Jeff Carroll (University of Washington)

9:45 Synergy in stimulating FXN expression by co-treatment with Synthetic Genome Regulators (SynGR1) and molecules that stabilize active chromatin marks
Prof. Aseem Ansari (St. Jude Children's Research Hospital)

10:00 Preliminary Results from SUNRISE-FA: A Phase1/2 Study of Investigational Gene Therapy, LX2006, for Cardiomyopathy of Friedreich Ataxia
Dr. Theresa Zesiewicz (University of South Florida)

10:15 The efficacy of a 30-week goal-directed rehabilitation program for individuals with hereditary cerebellar ataxia, a randomised controlled trial.
Prof. Martin Delatycki (Monash University, Murdoch Children’s Research Institute, University of Melbourne, Victorian Clinical Genetics Service)

10:30am Refreshments Break

11:00am Parallel sessions
Venue: *Trinity & Goodmans Suite*

Workshops
Minories Suite

Parallel session: Biomarkers and Clinical Outcomes II

Chaired by: Dr. Thomas Klockgether (German Center for Neurodegenerative Diseases - DZNE), Dr. Tanja Schmitz-Hübsch (Charité–Universitätsmedizin Berlin)

11:00 Assessing Progression in Ataxias - The Rating Scale Dilemma
Dr. Christian Rummey (Clinical Data Science GmbH)

11:15 A Longitudinal Analysis of One-Year Spinocerebellar Ataxia (SCA) Progression using the Patient-Reported Outcome Measure of Ataxia (PROM-Ataxia)
Ms. Anna L. Burt (Massachusetts General Hospital and Harvard Medical School)

Workshop: Overcoming Common Pitfalls in Patient Communications - How to engage patient participation in ataxia research

Ms. Alexa Putka (University of Michigan)
 Magda Matos Santana (University of Coimbra)
 Dr. Penina Ponger (Tel Aviv Sourasky Medical Center)

This workshop will provide an introduction to the challenges associated with patient communication in the ataxia field, including dissemination of results from preclinical and clinical studies, and the tools available to overcome these challenges.

Speakers
 Science Communication Strategies for Basic Research
Dr Celeste Suart (National Ataxia Foundation)

Enhancing Patient Engagement in Longitudinal Cohort Studies

11:30	<p>Longitudinal progression of digital gait measures in patients with spastic paraplegia type 7 (SPG7): an international multi-center study (PROSPAX)</p> <p><u>Dr. Lukas Beichert</u> (University of Tübingen)</p>	<p><u>Prof Manuela Lima</u> (University of the Azores)</p> <p>The Importance of Patient Communications in Clinical Trials</p> <p><u>Ms Maureen Juip</u> (FARA)</p>
11:45	<p>Longitudinal MRI reveals early structural changes in pre-symptomatic SCA3: A one- and two-year follow-up study</p> <p><u>Ms. Mónica Ferreira</u> (German Center for Neurodegenerative Diseases)</p>	
12:00	<p>Unusual age-dependent behaviour of Leukocyte Telomere Length in Friedreich's ataxia</p> <p><u>Dr. Suran Nethisinghe</u> (University College London)</p>	
12:07	<p>Cerebellum as geometrical object: Investigating SCA disease patterns in cerebellar shape analysis using graph neural networks and explainable AI</p> <p><u>Mr. Philipp Wegner</u> (German Center for Neurodegenerative Diseases)</p>	
12:14	<p>Responsiveness and predictive value of biomarkers in SCA1: Insights from a two-year multimodal longitudinal study</p> <p><u>Mr. Teije van Prooije</u> (Radboud University Medical Center)</p>	
12:21	<p>How to improve statistical power in a trial with SCA2 patients</p> <p><u>Ms. Maylis Tran</u> (Sorbonne University, Institut de Cerveau-Paris Brain Institute, CNRS, INRIA, INSERM, AP-HP)</p>	

12:30pm Plenary session: Late Breaking

Venue: *Trinity & Goodmans Suite*

Chaired by: Prof. Massimo Pandolfo (McGill University), Dr. Jennifer Faber (German Center for Neurodegenerative Diseases - DZNE)

12:30 Frataxin loss in animals is rescued by intra-complex mutations in the mitochondrial iron sulfur cluster biosynthesis machinery

Dr Joshua Meisel (Harvard Medical School and Massachusetts General Hospital)

12:40 Myeloid CRISPR/Cas-9 repeat editing as a therapeutic approach for cerebellar neurodegeneration in Friedreich's ataxia.

Dr Carla Pernaci (University of California, San Diego)

12:50 Comparative Effectiveness of Troriluzole versus Untreated Natural History Cohorts in Spinocerebellar Ataxia Leveraging Propensity Score Matching Methods

Dr Melissa Beiner (Biohaven Pharmaceuticals, Inc.)

1:00-1:10pm Final remarks

Venue: *Trinity & Goodmans Suite*

Prof. Massimo Pandolfo (McGill University), Dr. Marek Napierala (University of Texas Southwestern Medical Center)

2:00pm Euro Ataxia begins - Flash Talks for Patients

Venue: *Minories Suite*